First Liver Transplant Surgery Performed in Patient With CRC Metastases

Federico Aucejo, MD
Published: Wednesday, Feb 28, 2018
cleveland-clinicSFederico Aucejo, MD
Federico Aucejo, MD
 
Surgical Director
Liver Cancer Program
Cleveland Clinic
Cleveland, Ohio
Strategic Partnership
The prognosis for patients with liver metastases developing from colorectal cancer (CRC) is dismal. Although the standard-of-care treatment for this condition is liver resection, only one-third of these patients are candidates for surgery. The 5-year survival rate for this small subset of patients hovers between 25% and 60%. The remaining patients are treated with systemic chemotherapy as the standard of care; however, the 5-year survival rate for systemic chemotherapy is only about 10%, with a median survival of about 24 months.

To improve patient outcomes, physicianresearchers in Cleveland Clinic’s Liver Cancer Program have developed a new transplantation protocol for treating liver metastases from CRC. The team implemented the protocol to treat a patient with unresectable liver metastases from CRC, marking the first time that liver transplant surgery was performed for this indication in the United States.

The patient, whose cousin served as the live liver donor, had unresectable metastases in the liver, as well as liver disease from long-term chemotherapy toxicity. Following the successful procedure, both patient and donor were discharged from the hospital within the expected time frame.

We hope that by demonstrating the benefit of this approach, we can prolong the life of a significant number of patients who are not candidates for liver resection.

Norwegian Pilot Study

Cleveland Clinic began developing its new surgical protocol based on the results of a 2011 pilot study of 21 patients at the University of Oslo in Norway. The results of the study showed that liver transplantation helped patients with CRC unresectable liver metastases achieve a 5-year survival rate of 60%.1

The investigators found that metastatic recurrence of disease was common, particularly pulmonary recurrence. However, a significant proportion of the recurrences were accessible for surgery, and at follow-up (after a median of 27 months; range 8-60), 33% of patients had no evidence of disease. Prognostic factors included hepatic tumor load before liver transplantation, time from primary surgery to liver transplantation, and progressive disease on chemotherapy.

Proving Long-Term Efficacy and Shifting to Cadaver Donors

Now that the new protocol has been successfully employed with a patient, the next phase in research development involves proving long-term efficacy and shifting to cadaver donors. Initially, live donors for the transplants were identified because of the uncertainty of long-term oncological outcomes.

This uncertainty stems from the close association between immunosuppression therapy and posttransplant tumor recurrence. The investigators’ rationale was that if the initial experience performing liver transplantation in patients with liver metastases from CRC using live donors was promising, accessing the cadaveric pool would become easier in the future.

From an oncological standpoint, the transplant team’s goal is to achieve a 5-year survival rate of at least 50%. If the researchers can prove that the new protocol results in that rate, they will be able to justify this indication for transplantation.

Chemotherapy Infusion Pump

Along with the new transplant protocol, the Liver Cancer Program incorporated a hepatic artery chemotherapy infusion pump protocol for patients with disease limited to the liver. So far, clinicians have performed 13 pump implantations in combination with liver surgery to treat metastases from CRC.

In addition to systemic chemotherapy, patients have a chemotherapy pump that is implanted into the abdominal wall. The pump is connected to a catheter that is inserted into one of the arteries that connects to the liver. By infusing chemotherapy directly into the liver, the pump treats liver metastases more efficiently by preventing tumor recurrence after surgery or by reducing the bulk of disease so that it can be subsequently removed using surgery.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x